2 assets in Spindle Cell Neoplasm

Therapeutic assets addressing Spindle Cell Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Spindle Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Spindle Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)